Prevention of hepatitis B and C in the EU/EEA and the UK
Urgent action is required to improve efforts to prevent hepatitis B and C infections in the EU/EEA and the UK if the region is to meet the 2020 targets for the elimination of viral hepatitis as a serious threat to public health. Significant gaps in the reported data in relation to prevalence and prevention of HBV and HCV in EU/EEA and the UK present a major challenge to monitoring progress towards the targets for elimination of hepatitis.
Monitoring the responses to hepatitis B and C epidemics in the EU/EEA Member States, 2019
This report provides the first collation of data relating to the monitoring of the progress towards the elimination of hepatitis B and C for EU/EEA countries.
Hepatitis B and C among healthcare workers and patient groups at increased risk of iatrogenic transmission in the European Union/European Economic Area
Tavoschi, L., Mason, L., Petriti, U., Bunge, E., Veldhuijzen, I., Duffell, E.
Hepatitis b and c prevalence and incidence in key population groups with multiple risk factors in the EU/ EEA: A systematic review
Mason, L.M.K., Duffell, E., Veldhuijzen, I.K., Petriti, U., Bunge, E.M., Tavoschi, L.
Hepatitis C - Annual Epidemiological Report for 2017
In 2017, 31 273 cases of hepatitis C were reported in 29 EU/EEA Member States. Excluding countries that only reported acute cases, 31 178 cases corresponds to a crude rate of 7.3 cases per 100 000 population.
Hepatitis B and C epidemiology in selected population groups in the EU/EEA
The findings presented in this report will be part of the process of developing a European guidance for HBV and HCV testing and may provide support EU/EEA countries in the development of national guidelines and in the design and scale-up of testing interventions.
Public health guidance on prevention and control of blood-borne viruses in prison settings
This document provides EU/EEA Member States with evidence-based scientific advice on available options, when planning and implementing prevention and control interventions for blood-borne viruses in prison settings.
Guidance in brief: Prevention and control of blood-borne viruses in prison settings
This guidance is intended for policymakers responsible for the planning and delivery of healthcare services in the national or sub-national custodial system and all professionals responsible for the health and well-being of people in prison, including community-based service providers and those facilitating continuity of care in the community.
Systematic review on the prevention and control of blood-borne viruses in prison settings
The objective of this report was to systematically review data on prevention and control of BBVs in prison settings, with a focus on the countries of the European Union (EU) and the European Economic Area (EEA).
Public health guidance on active case finding of communicable diseases in prison settings
This joint guidance from ECDC and the European Monitoring Centre for Drugs and Drug Addiction provides EU/EEA Member States with evidence-based scientific advice on active case finding options. These options can be applied to the planning and implementation of interventions that promote the early diagnosis of communicable diseases in prison settings.